Skip to main navigation Skip to search Skip to main content

Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report

  • J. Salmanton-Garcia*
  • , F. Marchesi
  • , M. Navratil
  • , K. Piukovics
  • , Principe M. I. del
  • , Marianna Criscuolo
  • , Y. M. Bilgin
  • , N. S. Fracchiolla
  • , A. Vena
  • , A. Romano
  • , I. Falces-Romero
  • , N. Sgherza
  • , I. Heras-Fernando
  • , M. M. Biernat
  • , V. Petzer
  • , P. Zak
  • , B. Weinbergerova
  • , M. Samarkos
  • , N. Erben
  • , J. van Praet
  • A. Lopez-Garcia, J. Labrador, T. Lahmer, L. Drgona, M. Merelli, A. Cuccaro, S. Martin-Perez, J. Davila-Valls, F. Farina, C. Cattaneo, L. I. Pinczes, F. Magyari, I. Espigado, C. Buquicchio, D. C. Vinh, I. Stoma, M. Cernan, L. Prezioso, M. V. Papa, G. Plantefeve, R. A. Khedr, J. Batinic, G. Magliano, S. Erdem, S. Khostelidi, N. Colovic, D. Nappi, P. Garcia-Ramirez, J. Gora, M. Callejas-Charavia, J. Tlusty, M. Bakker, E. Wojtyniak, D. Antic, A. Magdziak, M. Dargenio, L. Idrizovic, N. Pantic, Z. Stojanoski, N. Eisa, V. Otasevic, M. Marchetti, E. Mackenzie, C. Garcia-Vidal, A. Aujayeb, A. Almasari, C. Miranda-Castillo, E. Gavriilaki, N. Coppola, A. Busca, T. Adzic-Vukicevic, M. Schonlein, D. S. Hersby, S. K. Grafe, A. Glenthoj, T. F. Aiello, M. Cvetanoski, M. Mitrovic, C. Cerchione, R. Prin, G. Varricchio, E. Arellano, R. Cordoba, J. Mayer, B. Visek, D. Wolf, A. N. Anastasopoulou, M. Delia, P. Musto, D. Leotta, M. Bavastro, A. Limongelli, M. Sciume, L. van den Ven, Luana Fianchi, S. C. Brunetti, J. Drozd-Sokolowska, A. Dabrowska-Iwanicka, O. A. Cornely, Livio Pagano*
*Corresponding author
  • IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena
  • University of Szeged
  • University of Genoa
  • San Martino Hospital Genoa
  • AOU Policlinico Rodolico San Marco
  • Centro de Investigación Biomédica en Red
  • La Paz University Hospital
  • AOUC Policlinico
  • Hospital Morales Meseguer
  • Innsbruck Medical University
  • National and Kapodistrian University of Athens
  • Osmangazi University
  • AZ Sint-Jan Brugge-Oostende AV
  • Hospital Universitario de Burgos
  • Technical University of Munich
  • Integrata
  • IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
  • Azienda USL Toscana NordOvest
  • San Raffaele Scientific Institute
  • Spedali Civili Di Brescia
  • University of Debrecen
  • Hospital Universitario Virgen del Rocio
  • Ospedale Dimiccoli Barletta
  • Gomel State Medical University
  • Azienda Ospedaliero - Universitaria di Parma
  • Centre Hospitalier Victor Dupouy d'Argenteuil
  • Asst Grande Ospedale Metropolitano Niguarda
  • Istanbul University
  • North-Western State Medical University named after I.I. Mechnikov
  • IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori - Meldola (FC)
  • Hospital Universitari Principe de Asturias
  • University of Groningen
  • Maria Sklodowska-Curie Institute of Oncology
  • Ospedale Vito Fazzi
  • Medical Faculty
  • Mansoura University
  • King Faisal Specialist Hospital and Research Centre
  • Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo
  • University of Kansas
  • University of Barcelona
  • Northumbria Healthcare NHS Trust
  • Hospital Rey Juan Carlos
  • George Papanikolaou General Hospital of Thessaloniki
  • University of Campania Luigi Vanvitelli
  • Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino
  • Azienda Ospedaliera Sant' Anna e San Sebastiano
  • Masaryk University
  • University of Cologne

Research output: Contribution to journal › Article

Abstract

Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.
Original languageEnglish
Pages (from-to)358-374
Number of pages17
JournalAmerican Journal of Hematology
Volume100
Issue number3
DOIs
Publication statusPublished - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Hematology

Keywords

  • antiviral therapy
  • community-acquired respiratory viral infection
  • hematological malignancy
  • secondary infection
  • vaccine coverage

Fingerprint

Dive into the research topics of 'Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report'. Together they form a unique fingerprint.

Cite this